Over the past several years, there has been an increasing interest in the use of nanoparticles as a tool for treatment of cancer. We have shown tremendous augmentation and control (without toxicity) of both heat and cold-based thermal therapy for cancer treatment with a gold based nanodrug-CYT-6091 (Cytimmune Sciences, Inc.) [1–3]. To reach the full potential of these nanodrugs for both stand-alone solid cancer treatment and as adjuvant to thermal therapy, there is a need to understand the in vivo biodistribution and their short-term and long-term tissue interaction.

This content is only available via PDF.
You do not currently have access to this content.